The analgesic efficacy of celecoxib in patients with malignancies has been extensively studied for its ability to reduce inflammation and pain response by selectively inhibiting COX-2 and decreasing prostaglandin synthesis, and is commonly used for mild to moderate pain caused by cancer, and in a study by Hou et al., the addition of celecoxib was effective in improving pain in patients with carcinomatous neuralgia (Hou et al., 2021). This evidence concerns the gene PTGS2 and cancer.